|
Myelodysplastic Syndromes: A Review of Therapeutic Progress Over the Past 10 Years |
Jun 2020 |
Expert Review of Anticancer Therapy |
Myelodysplastic Syndromes (MDS) |
|
SF3B1 Mutations Negatively Predict for Response to Immunosuppressive Therapy in Myelodysplastic Syndromes |
Jun 2020 |
Clinical Lymphoma , Myeloma & Leukemia |
Myelodysplastic Syndromes (MDS) |
|
Wide Variation in Use and Interpretation of Gene Mutation Profiling Panels Among Health Care Providers of Patients With Myelodysplastic Syndromes: Results of a Large Web-Based Survey |
Jun 2020 |
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
|
How I Diagnose Low-Grade Myelodysplastic Syndromes |
May 2020 |
American Journal of clinical Pathology |
Myelodysplastic Syndromes (MDS) |
|
Controversies on the Consequences of Iron Overload and Chelation in MDS |
May 2020 |
HemaSphere |
Myelodysplastic Syndromes (MDS) |
|
Myelodysplastic Syndromes: Moving Towards Personalized Management |
May 2020 |
Haematologica |
Myelodysplastic Syndromes (MDS) |
|
Secondary Myelodysplastic Syndrome and Leukemia in Acquired Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria |
May 2020 |
Blood |
Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Genetics of Progression From MDS to Secondary Leukemia |
May 2020 |
Blood |
Myelodysplastic Syndromes (MDS) |
|
Immunosuppression and Growth Factors for Severe Aplastic Anemia: New Data for Old Questions |
May 2020 |
Haematologica |
Aplastic Anemia |
|
Baseline Clinical Characteristics and Disease Burden in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH): Updated Analysis From the International PNH Registry |
May 2020 |
Annals of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
